DOCSLIB.ORG

Late Effects of Treatment

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Late Effects of Treatment Late Effects of Treatment A Guide for Patients Introduction Your cancer treatment can cause side effects. Some of these will occur at the time of treatment and will normally stop when treatment ends. Some of these side effects may last for a long time after treatment; these are long- term effects. Some side effects do not occur for months or even years after treatment ends; these side effects are called late effects. These late effects can be physical or emotional. Not everyone gets late effects, the risk depends on the type of treatment, the dose of treatment and the patient’s age at the time of treatment. This booklet is designed to and peer reviewed by Dr Panos provide you with information Kottaridis, Royal Free Hospital. about the late effects you may The rewrite was put together by experience, what to expect and Lisa Lovelidge and reviewed by how they may be managed. If Dr Victoria Grandage. We are also you need specific advice or are grateful to our patient reviewers, concerned about a particular Simon Walker, John Watson and late effect, please contact your Steve Colbourne and the Brighton medical team or Clinical Nurse support group. The booklet has Specialist. since been updated by our Patient Information Writer, Isabelle Leach. This booklet has been compiled by Dr Victoria Grandage (UCLH) If you would like any information on the sources used for this booklet, please email [email protected] for a list of references. Version 3 Printed: 10/2020 2 www.leukaemiacare.org.uk Review date: 10/2022 In this booklet Introduction 2 In this booklet 3 About Leukaemia Care 4 A note from our patient services team 6 The different types of side effects 8 Fatigue 10 Eye, hearing and mouth changes 12 Skin and nail side effects 14 Bone and joint issues 16 Endocrine changes 18 Cognitive function effect 22 Lymphoedema 23 Lung toxicity 24 Heart toxicity 26 Kidney and liver toxicity 28 Nerve side effects 31 Secondary cancers 32 Managing late effects 34 Glossary 38 Useful contacts and further support 43 Helpline freephone 08088 010 444 3 About Leukaemia Care Leukaemia Care is a national charity dedicated to ensuring that people affected by blood cancer have access to the right information, advice and support. Our services has been affected by a blood cancer. A full list of titles – both Helpline disease specific and general Our helpline is available 8:30am information titles – can be – 5:00pm Monday - Friday and found on our website at www. 7:00pm – 10:00pm on Thursdays leukaemiacare.org.uk/support- and Fridays. If you need someone and-information/help-and- to talk to, call 08088 010 444. resources/information-booklets/ Alternatively, you can send Support Groups a message via WhatsApp on Our nationwide support groups 07500068065 on weekdays are a chance to meet and talk 9:00am – 5:00pm. to other people who are going Nurse service through a similar experience. For more information about a We have two trained nurses on support group local to your area, hand to answer your questions go to www.leukaemiacare.org. and offer advice and support, uk/support-and-information/ whether it be through emailing support-for-you/find-a-support- [email protected] or group/ over the phone on 08088 010 444. Buddy Support Patient Information Booklets We offer one-to-one phone We have a number of patient support with volunteers who have information booklets like had blood cancer themselves this available to anyone who or been affected by it in some 4 www.leukaemiacare.org.uk way. You can speak to someone Website who knows what you are going You can access up-to-date through. For more information information on our website, on how to get a buddy call www.leukaemiacare.org.uk. 08088 010 444 or email [email protected] Campaigning and Advocacy Online Forum Leukaemia Care is involved in campaigning for patient well- Our online forum, being, NHS funding and drug www.healthunlocked.com/ and treatment availability. If you leukaemia-care, is a place would like an update on any of for people to ask questions the work we are currently doing or anonymously or to join in the want to know how to get involved, discussion with other people in a email advocacy@leukaemiacare. similar situation. org.uk Patient and carer conferences Patient magazine Our nationwide conferences Our magazine includes provide an opportunity to inspirational patient and carer ask questions and listen to stories as well as informative patient speakers and medical articles by medical professionals: professionals who can provide www.leukaemiacare.org.uk/ valuable information and support. communication-preferences/ Helpline freephone 08088 010 444 5 A note from our Patient Services team We know that sometimes the late effects of treatment can be more difficult to manage than the illness itself. Sometimes the effects can be unexpected or more severe than you anticipated. We are aware that many patients have lots of questions about the late effects of treatment and how to deal with them and we hope this booklet helps to answer some of them. We have indicated the effects that are most commonly experienced by patients and not all late effects feature in this booklet. This does not mean that what you are experiencing is not related to your illness or treatment, so if you are at all worried, please speak to your medical team. If you have any questions about the information in this booklet or you want to know where you can get more information, please call us on 08088 010 444, where a member of the Patient Services team or a dedicated trained volunteer will be ready to answer your questions. Best wishes, The Patient Services Team 6 www.leukaemiacare.org.uk Helpline freephone 08088 010 444 7 The different types of side effects Most of the treatments used late side effect. for patients with leukaemia Long-term side effects: Side (chemotherapies, chemo • effects that are permanent and immunotherapies, radiotherapy remain long after treatment and stem cell transplants) can is finished. The development cause side effects. However, not of lung fibrosis 10 years after everyone experiences side effects treatment is an of example of a with treatment since people react long-term side effect. differently, and some patients do not have any side effects at all. Acute side effects of Side effects from treatment may treatments for leukaemia be acute, late or long-term. and have been discussed in are distinguished as followed: our booklet Common Side • Acute side effects: Side Effects of Treatment. You effects that occur during and can download a copy of the immediately after treatment. booklet from our website Most side effects are short-lived at www.leukaemiacare. and reversible, disappearing org.uk or request a copy after treatment ends. For by emailing support@ example, nausea and hair loss leukaemiacare.org.uk occur at the time of receiving or calling the helpline on treatment and usually stop 08088 010 444. once the drug is stopped. Late side effects: Side effects • In this booklet, we discuss the that occur after treatment and late side effects and long-term may continue for a certain side effects of treatment for period after treatment is leukaemia. These side effects may finished. These are also known be physical or emotional and may as delayed side effects. Bone not show up for months or years loss occurring two years after after you have finished treatment. treatment is an example of a Late and long-term side effects 8 www.leukaemiacare.org.uk Helpline freephone 08088 010 444 8 vary from patient to patient, • Eye, hearing and mouth ranging from very mild to serious. changes Not everyone gets late effects; the Skin and nail side effects risk depends on type of treatment, • dose and age when treated. • Bone and joint issues When you receive follow-up • Endocrine and thyroid changes care, your haematologist will discuss any possible late or long- • Cognitive or thinking effects term side effects that you may • Lung toxicity experience because early medical attention often can lessen any • Heart toxicity issues that can come from late or Nerve side effects long-term side effects. • Kidney and urinary toxicity As treatments for leukaemia • have become more effective, • Secondary cancers our knowledge of late and long- term side effects has increased. Many newer treatments have been developed to reduce the number and intensity of late, and particularly long-term, side effects. Certainly, many of the treatments used now are much less likely to cause health problems than those used 20 years ago. Possible late and long-term side effects of patients receiving cancer treatment include: • Fatigue Helpline freephone 08088 010 444 9 Fatigue Fatigue may be experienced adrenal-axis is the name for a during treatment, but it can also complex pathway of hormonal last for years after treatment is interactions between the finished. It is one of the most hypothalamus and pituitary common long-term side effects gland in the brain and the adrenal and is experienced by 33% of glands situated on top of the patients with acute myeloid kidneys (Figure 1). It is known leukaemia. as the central stress response system and links the central Fatigue is a tiredness or feeling nervous system and endocrine of exhaustion which leaves you system. unable to work or perform your usual activities. Fatigue can be Other more obvious causes of late experienced either physically or or long-term fatigue can include: psychologically, and can affect Ongoing pain. your ability to do everyday tasks, • as well as your mental ability. • Chemotherapy with drugs such as vincristine, vinblastine, and The reasons why persistent cisplatin often cause fatigue fatigue occurs following through and beyond completion treatment for cancer are not yet of treatment.
Load more

Recommended publications
  • Late Effects of Therapy in Childhood Acute Lymphoblastic Leukemia Survivors REVIEW
    REVIEW DOI: 10.4274/tjh.galenos.2018.2018.0150 Turk J Hematol 2019;36:1-11 Late Effects of Therapy in Childhood Acute Lymphoblastic Leukemia Survivors Çocukluk Çağı Akut Lenfoblastik Lösemi Tedavisi Sonrası Geç Yan Etkiler Hande Kızılocak1, Fatih Okcu2 1Istanbul University-Cerrahpaşa Faculty of Medicine, Department of Pediatric Hematology and Oncology, İstanbul, Turkey 2Texas Children’s Hematology and Oncology Centers, Baylor College of Medicine, Department of Pediatrics, Division of Hematology and Oncology, Houston, TX, USA Abstract Öz Over the last 50 years, the survival rates in children with acute Son 50 yıldaki gelişmeler ile akut lenfoblastik lösemili (ALL) lymphoblastic leukemia (ALL) have increased remarkably. The optimal çocuklardaki tedavi sonrası sağkalım oranında belirgin derecede artış use of antileukemic agents in cooperative group protocols, central saptandı. Antilösemik ilaçların akılcı kullanımı, santral sinir sistemini nervous system-directed treatment, improvements in supportive hedefleyen lokal tedaviler ve destek tedavisindeki gelişmeler ile 5 care, and recognition of biological, clinical, and treatment response yıllık olaysız sağkalım %85’e ve 5 yıllık genel sağkalım %90’a ulaştı. characteristics that predict patients with a higher or a lower risk of Uzamış sağkalım süreleri, tedavinin uzun dönem yan etkilerine olan treatment failure have improved 5-year event-free survival rates, farkındalığı da arttırdı. Geç dönem mortalite, ikincil maligniteler, reaching more than 85%, and 5-year overall survival rates, reaching
    [Show full text]
  • ICD-10-CM Official Guidelines for Coding and Reporting FY 2016
    ICD-10-CM Official Guidelines for Coding and Reporting FY 2016 Narrative changes appear in bold text Items underlined have been moved within the guidelines since the FY 2014 version Italics are used to indicate revisions to heading changes The Centers for Medicare and Medicaid Services (CMS) and the National Center for Health Statistics (NCHS), two departments within the U.S. Federal Government’s Department of Health and Human Services (DHHS) provide the following guidelines for coding and reporting using the International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM). These guidelines should be used as a companion document to the official version of the ICD-10- CM as published on the NCHS website. The ICD-10-CM is a morbidity classification published by the United States for classifying diagnoses and reason for visits in all health care settings. The ICD-10-CM is based on the ICD-10, the statistical classification of disease published by the World Health Organization (WHO). These guidelines have been approved by the four organizations that make up the Cooperating Parties for the ICD-10-CM: the American Hospital Association (AHA), the American Health Information Management Association (AHIMA), CMS, and NCHS. These guidelines are a set of rules that have been developed to accompany and complement the official conventions and instructions provided within the ICD-10-CM itself. The instructions and conventions of the classification take precedence over guidelines. These guidelines are based on the coding and sequencing instructions in the Tabular List and Alphabetic Index of ICD-10-CM, but provide additional instruction.
    [Show full text]
  • ICD-10-CM Official Guidelines for Coding and Reporting FY 2018 (October 1, 2017 - September 30, 2018)
    ICD-10-CM Official Guidelines for Coding and Reporting FY 2018 (October 1, 2017 - September 30, 2018) Narrative changes appear in bold text Items underlined have been moved within the guidelines since the FY 2017 version Italics are used to indicate revisions to heading changes The Centers for Medicare and Medicaid Services (CMS) and the National Center for Health Statistics (NCHS), two departments within the U.S. Federal Government’s Department of Health and Human Services (DHHS) provide the following guidelines for coding and reporting using the International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM). These guidelines should be used as a companion document to the official version of the ICD-10- CM as published on the NCHS website. The ICD-10-CM is a morbidity classification published by the United States for classifying diagnoses and reason for visits in all health care settings. The ICD-10-CM is based on the ICD-10, the statistical classification of disease published by the World Health Organization (WHO). These guidelines have been approved by the four organizations that make up the Cooperating Parties for the ICD-10-CM: the American Hospital Association (AHA), the American Health Information Management Association (AHIMA), CMS, and NCHS. These guidelines are a set of rules that have been developed to accompany and complement the official conventions and instructions provided within the ICD-10-CM itself. The instructions and conventions of the classification take precedence over guidelines. These guidelines are based on the coding and sequencing instructions in the Tabular List and Alphabetic Index of ICD-10-CM, but provide additional instruction.
    [Show full text]
  • Late Effects of Cancer Treatments Noreen M
    6 Late Effects of Cancer Treatments Noreen M. Aziz Background and Significance such as cigarette smoke or toxins such as alcohol are largely unknown.2,6,12 With continued advances in strategies to detect cancer early Thus, there is today a greater recognition of symptoms and treat it effectively, along with the aging of the population, that persist after the completion of treatment and which arise the number of individuals living years beyond a cancer diag- years after primary therapy. Both acute organ toxicities such nosis can be expected to continue to increase. Statistical as radiation pneumonitis and chronic toxicities such as con- trends show that, in the absence of other competing causes gestive cardiac failure, neurocognitive deficits, infertility, and of death, 64% of adults diagnosed with cancer today can second malignancies are being described as the price of cure 2,6,12 expect to be alive in 5 years.1–4 Relative 5-year survival rates or prolonged survival. The study of late effects, originally for those diagnosed as children (age less than 19 years) are within the realm of pediatric cancer, is now germane to even higher, with almost 79% of childhood cancer survivors cancer survivors at all ages because concerns may continue 2,6 estimated to be alive at 5 years and 75% at 10 years.5 to surface throughout the life cycle. These concerns under- Survival from cancer has seen dramatic improvements score the need to follow up and screen survivors of cancer for over the past three decades, mainly as a result of advances in toxicities such as those mentioned and also to develop and early detection, therapeutic strategies, and the widespread use provide effective interventions that carry the potential to of combined modality therapy (surgery, chemotherapy, and prevent or ameliorate adverse outcomes.
    [Show full text]
  • Laughter Is the Best Medicine
    SUMMER 2019 • ISSUE 83 • Late effects A helping hand for families of children and young people with cancer Laughter is the best medicine Lynda McMahon shares her son Benjamin’s story, from intensive cancer treatment as a child to his debut in a successful West End comedy play. Benjamin was diagnosed with acute lymphoblastic leukaemia (ALL) when he Benjamin and his family was four years old and he went through three years of intensive chemotherapy. For Benjamin, the challenges were multiplied as he contracted pneumonia in the midst of his treatment. He was on life support and put into a drug-induced coma in the intensive care unit at The John Radcliffe Hospital in Oxford. Thanks to the professionalism of his medical teams and, most importantly, his own sheer determination, he pulled through with no brain damage, which we were told he may have suffered due to the period he was starved of oxygen. He spent a month in hospital learning to walk again and gaining strength before restarting chemotherapy as he still had the leukaemia to fight. Unfortunately, Benjamin’s cancer returned after 18 months of remission. He needed a further two years of chemotherapy and had cranial radiotherapy too as the leukaemia had reappeared in the fluid around his brain. With over 70 lumbar punctures and many general anaesthetics, viral encephalitis, shingles and a host of other infections and complications, this was more than enough for one little body. Benjamin missed a lot of school and INSIDE What are Coping with The science had to contend with being dyslexic THIS late effects? emotional late effects behind late effects Pages 6-7 Page 8 Page 10 (...continued on page 2) ISSUE: 2 Contact Issue 83: Late effects audience laugh out loud was so Cover story continued..
    [Show full text]
  • ICD-10 Coding Help Sheet
    ICD-10 Coding Help Sheet Abnormal Breathing Signs Aftercare: Acute Respiratory Distress – R06.03 Amputation – Z47.81 Apnea – R06.81 Note: Use additional code to identify Dyspnea – R06.00 limb amputated Z89.+++ Cheyne-Stoke (Periodic) – R06.3 Note: If due to DM ulcer add code Hyperventilation – R06.4 for the history of DM ulcer Z86.31 Orthopnea – R06.01 Breast Reconstruction, Post-Mastectomy – Shortness of Breath – R06.02 Z42.1 Stridor – R06.2 Fracture – Code the fracture Tachypnea – R06.82 Joint Explanation (staged procedure, Wheezing – R06.2 including a subsequent joint Abnormality of Gait replacement) - Z47.3+ Ataxic (staggering) Gait – R26.0 Note: If removed and not replaced Paralytic (spastic) Gait – R26.1 code the acquired absence of a joint Difficulty Walking (chronic limp) – R26.2 Hip – Z89.62+ Unsteadiness on feet – R26.81 Knee – Z89.52+ Musculoskeletal/Other – R26.89 Shoulder – Z89.23+ Unspecified – R26.9 Joint Replacement - Z47.1 Abnormal Weight Loss – R63.4 Note: Use additional code to identify Abrasion – See Superficial Skin Injury the joint Z96.6++ Absence of: Neoplasm Removal – Z48.3 Arm, Above Elbow – Z89.22+ Note: Use additional code to Arm, Below Elbow) – Z89.21+ identify the neoplasm (continued Breast – Z90.1+ treatment) or history of neoplasm Foot – Z89.43 (eradicated/no further treatment) Hand – Z89.11 Ortho NEC – Z47.89 Joint Note: Used for other orthopedic Hip – Z89.62+ surgeries, e.g. spinal surgery Knee – Z89.53+ Ostomies – Z43.+ Shoulder – Z89.23 Post-procedural Wound Closure – Z48.1 Leg, Above Knee – Z89.61+ Specified Body System Leg, Below Knee – Z89.51+ Sensory – Z48.810 Toe, Great – Z89.41 Neurological - Z48.811 Toe(s), Other – Z89.42 Circulatory - Z48.812 Abscess Respiratory - Z48.813 Abdominal Wall – L02.211 Digestive - Z48.815 Buttocks – L02.31 Genitourinary - Z48.816 Face – L02.01 Integumentary - Z48.817 Foot – L02.61+ Transplant – Z48.2+ Hand – L02.51+ Note: Aftercare is not coded if due to Limb – L02.41+ trauma, injury or if a complication is present.
    [Show full text]
  • ICD-9-CM Official Guidelines for Coding and Reporting
    ICD-9-CM Official Guidelines for Coding and Reporting Effective October 1, 2011 Narrative changes appear in bold text Items underlined have been moved within the guidelines since October 1, 2010 The Centers for Medicare and Medicaid Services (CMS) and the National Center for Health Statistics (NCHS), two departments within the U.S. Federal Government’s Department of Health and Human Services (DHHS) provide the following guidelines for coding and reporting using the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM). These guidelines should be used as a companion document to the official version of the ICD-9- CM as published on CD-ROM by the U.S. Government Printing Office (GPO). These guidelines have been approved by the four organizations that make up the Cooperating Parties for the ICD-9-CM: the American Hospital Association (AHA), the American Health Information Management Association (AHIMA), CMS, and NCHS. These guidelines are included on the official government version of the ICD-9-CM, and also appear in “Coding Clinic for ICD-9-CM” published by the AHA. These guidelines are a set of rules that have been developed to accompany and complement the official conventions and instructions provided within the ICD-9-CM itself. The instructions and conventions of the classification take precedence over guidelines. These guidelines are based on the coding and sequencing instructions in Volumes I, II and III of ICD-9-CM, but provide additional instruction. Adherence to these guidelines when assigning ICD-9-CM diagnosis and procedure codes is required under the Health Insurance Portability and Accountability Act (HIPAA).
    [Show full text]
  • (001-139) Includes: Diseases Generally Recogniz
    ICD9 Cause of Death list 1 of 609 CLASSIFICATION OF DISEASES AND INJURIES I. INFECTIOUS AND PARASITIC DISEASES (001-139) Includes: diseases generally recognized as communicable or transmissible as well as a few diseases of unknown but possibly infectious origin Excludes: acute respiratory infections (460-466) influenza (487.-) certain localized infections Note: Categories for "late effects" of infectious and parasitic diseases are to be found at 137.- to 139.- INTESTINAL INFECTIOUS DISEASES (001-009) Excludes: helminthiases (120-129) 001 Cholera 001.0 Due to Vibrio cholerae 001.1 Due to Vibrio cholerae el tor 001.9 Unspecified 002 Typhoid and paratyphoid fevers 002.0 Typhoid fever Typhoid (fever) (infection) [any site] 002.1 Paratyphoid fever A 002.2 Paratyphoid fever B 002.3 Paratyphoid fever C 002.9 Paratyphoid fever, unspecified 003 Other salmonella infections Includes: infection or food poisoning by Salmonella [any serotype] ICD9 Cause of Death list 2 of 609 003.0 Salmonella gastroenteritis Salmonellosis 003.1 Salmonella septicaemia 003.2 Localized salmonella infections Salmonella: Salmonella: arthritis osteomyelitis meningitis pneumonia 003.8 Other 003.9 Unspecified Salmonella infection NOS 004 Shigellosis Includes: bacillary dysentery 004.0 Shigella dysenteriae Infection by group A Shigella (Schmitz) (Shiga) 004.1 Shigella flexneri Infection by group B Shigella 004.2 Shigella boydii Infection by group C Shigella 004.3 Shigella sonnei Infection by group D Shigella 004.8 Other 004.9 Unspecified 005 Other food poisoning (bacterial) Excludes: salmonella infections (003.-) toxic effect of noxious foodstuffs (988.-) ICD9 Cause of Death list 3 of 609 005.0 Staphylococcal food poisoning Staphylococcal toxaemia specified as due to food 005.1 Botulism Food poisoning due to Clostridium botulinum 005.2 Food poisoning due to Clostridium perfringens [Cl.
    [Show full text]
  • Chronic Myeloid Leukemia
    Chronic Myeloid Leukemia Paula, CML survivor This publication was supported by Revised 2014 A Message from Louis J. DeGennaro, PhD President and CEO of The Leukemia & Lymphoma Society The Leukemia & Lymphoma Society (LLS) is the world’s largest voluntary health organization dedicated to finding cures for blood cancer patients. Our research grants have funded many of today’s most promising advances; we are the leading source of free blood cancer information, education and support; and we advocate for blood cancer patients and their families, helping to ensure they have access to quality, affordable and coordinated care. Since 1954, we have been a driving force behind almost every treatment breakthrough for blood cancer patients. We have invested more than $1 billion in research to advance therapies and save lives. Thanks to research and access to better treatments, survival rates for many blood cancer patients have doubled, tripled and even quadrupled. Yet we are far from done. Until there is a cure for cancer, we will continue to work hard—to fund new research, to create new patient programs and services, and to share information and resources about blood cancers. This booklet has information that can help you understand chronic myeloid leukemia (CML), prepare your questions, find answers and resources, and communicate better with members of your healthcare team. Our vision is that, one day, all people with CML will either be cured or will be able to manage their disease so that they can experience a great quality of life. Today, we hope our expertise, knowledge and resources will make a difference in your journey.
    [Show full text]
  • Late Effects of Childhood Cancer and Its Treatment
    Late Effects of Childhood Cancer and Its Treatment Wendy Landier, PhD, RN, Saro Armenian, DO, MPH, Smita Bhatia, MD, MPH* KEYWORDS Childhood Cancer Late effects Treatment KEY POINTS As survival rates for pediatric cancers continue to improve, the number of childhood cancer survivors continues to increase. The burden of long-term therapy-related morbidity experienced by childhood cancer survivors is substantial. Childhood cancer survivors require lifelong follow-up care to monitor for late treatment- related sequelae. INTRODUCTION With advances in therapeutic strategies for common childhood malignancies such as leukemia, lymphoma, and central nervous system (CNS) tumors, the number of child- hood cancer survivors in the United States continues to increase, and is estimated to exceed 500,000 by 2020.1 About 1 of every 530 young adults between 20 and 39 years of age in the United States is a childhood cancer survivor.2 Treatment of childhood cancer with chemotherapy, radiation, or hematopoietic cell transplant (HCT) can result in adverse sequelae, which may not become evident for many years. In this article, commonly occurring late effects associated with childhood cancer treatment are reviewed. BURDEN OF MORBIDITY The burden of morbidity experienced by childhood cancer survivors is substantial, as shown by the fact that approximately 40% of childhood cancer survivors experience a late effect that is severe, life threatening, disabling, or fatal at 30 years from diagnosis.3 A primary diagnosis of Hodgkin lymphoma (HL) or brain tumors and exposure to chest radiation or anthracyclines increases the risk of these chronic health conditions. Furthermore, the burden of morbidity increases as the cohort ages.4 HCT recipients experience a higher burden of morbidity when compared with childhood cancer Department of Population Sciences, City of Hope, 1500 E.
    [Show full text]
  • COG Long-Term Follow-Up Guidelines Guidelines Children’S Oncology Group
    Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers Version 5.0 - October 2018 Website: www.survivorshipguidelines.org Copyright 2018 © Children’s Oncology Group All rights reserved worldwide Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers Version 5.0 – October 2018 www.survivorshipguidelines.org Copyright 2018 © Children’s Oncology Group All rights reserved worldwide Generously supported by With special appreciation to Jocelyn M. York, BA, Institute for Cancer Outcomes and Survivorship University of Alabama at Birmingham Birmingham, AL for editing and typesetting Contents Introductory Materials Page Section # Page Sex Therapeutic Agent Potential Late Effect Abstract x 14 18 Female Alkylating Agents Reduced ovarian follicular pool Disclaimer and Notice of Proprietary Rights xi 15 20 Alkylating Agents Acute myeloid leukemia; Myelodysplasia Contributors - Panel of Experts xii 16 21 Alkylating Agents Pulmonary fi brosis Contributors - Task Force Membership 2013-2018 xiii 17 22 Alkylating Agents Cataracts Contributors - Guideline Development Task Force - Initial Versions xviii 18 23 Alkylating Agents Urinary tract toxicity Contributors - Health Link Authors xviii 19 24 Alkylating Agents Bladder malignancy Preface xix 20 25 Alkylating Agents Renal toxicity Instructions for Use xxiii 21 26 Heavy Metals Ototoxicity New to Version 5.0 xxvi 22 28 Heavy Metals Peripheral sensory neuropathy 23 29 Heavy Metals Renal toxicity Section # Page Sex Therapeutic Agent
    [Show full text]
  • Icd-10-Cm Fy 2021-Covid
    ICD-10-CM Official Guidelines for Coding and Reporting FY 2021 – UPDATED January 1, 2021 (October 1, 2020 - September 30, 2021) Narrative changes appear in bold text Items underlined have been moved within the guidelines since the FY 2020 version Italics are used to indicate revisions to heading changes The National Center for Health Statistics (NCHS) and the Centers for Medicare and Medicaid Services (CMS), two departments within the U.S. Federal Government’s Department of Health and Human Services (DHHS) provide the following guidelines for coding and reporting using the International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM). These guidelines should be used as a companion document to the official version of the ICD-10- CM as published on the NCHS website. The ICD-10-CM is a morbidity classification published by the United States for classifying diagnoses and reason for visits in all health care settings. The ICD-10-CM is based on the ICD-10, the statistical classification of disease published by the World Health Organization (WHO). These guidelines have been approved by the four organizations that make up the Cooperating Parties for the ICD-10-CM: the American Hospital Association (AHA), the American Health Information Management Association (AHIMA), CMS, and NCHS. These guidelines are a set of rules that have been developed to accompany and complement the official conventions and instructions provided within the ICD-10-CM itself. The instructions and conventions of the classification take precedence over guidelines. These guidelines are based on the coding and sequencing instructions in the Tabular List and Alphabetic Index of ICD-10-CM, but provide additional instruction.
    [Show full text]